Physician profile
Mohan Durve
NPI 1003866302
$33,635.58
in general payments reported to CMS, 2019-2025
37 companies · $4,126 in 2025
The $4,126 reported for 2025 was more than what 97% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,235 · 2020: $2,702 · 2021: $5,596 · 2022: $5,359 · 2023: $9,233 · 2024: $3,384 · 2025: $4,126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Consulting Fee: $3,581 · Travel and Lodging: $928 · Education: $71.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,164.21 |
| Consulting Fee | $3,580.52 |
| Travel and Lodging | $928.03 |
| Education | $71.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $6,130.21 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Genentech USA, INC. | $5,858.77 | 2019-2025 | Xolair |
| Csl Behring | $5,012.88 | 2019-2025 | Haegarda, Andembry, Hizentra |
| Genzyme Corporation | $2,103.83 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,101.04 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Novartis Pharmaceuticals Corporation | $1,832.31 | 2021-2025 | |
| Amgen INC. | $1,471.91 | 2019-2025 | Tezspire |
| Pfizer INC. | $1,432.32 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,100.80 | 2019-2025 | Dupixent |
| Genentech, INC. | $921.30 | 2021-2025 | Xolair |
| Biocryst US Sales Co., LLC | $905.15 | 2021-2025 | Orladeyo |
| Teva Pharmaceuticals USA, INC. | $868.47 | 2019-2022 | |
| Optinose US, INC. | $459.15 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $444.96 | 2020-2025 | Takhzyro, Cuvitru |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $334.00 | 2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $326.65 | 2023 | Opzelura |
| Biohaven Pharmaceuticals, INC. | $322.68 | 2021 | |
| Abbvie INC. | $301.05 | 2021-2022 | |
| Circassia INC. | $200.72 | 2021-2023 | Niox |
| Verona Pharma, INC. | $192.25 | 2025 | Ohtuvayre |
| Blueprint Medicines Corporation | $191.28 | 2022-2025 | Ayvakit |
| Biocryst Pharmaceuticals, INC. | $142.91 | 2020-2025 | Orladeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $129.57 | 2019 | |
| Allergan, INC. | $125.00 | 2020 | |
| Kaleo, INC. | $121.09 | 2021-2022 | |
| Regeneron Pharmaceuticals, INC. | $91.32 | 2022 | |
| Sanofi-Aventis U.S. LLC | $85.49 | 2021 | |
| Lilly USA, LLC | $75.38 | 2023 | Olumiant |
| Alk-Abello, INC | $75.00 | 2021 | |
| Pharming Healthcare, INC. | $58.28 | 2021-2025 | Ruconest |
| Cycle Pharmaceuticals INC | $55.72 | 2025 | Sajazir |
| Viatris Specialty LLC | $44.37 | 2025 | Yupelri |
| Merck Sharp & Dohme LLC | $31.93 | 2023 | |
| Mylan Specialty L.P. | $28.74 | 2024 | Yupelri |
| Jubilant Hollisterstier LLC | $22.81 | 2025 | |
| Hikma Pharmaceuticals USA | $22.63 | 2023 | Ryaltris |
| Ionis Pharmaceuticals, INC. | $13.61 | 2025 | Dawnzera |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohan Durve listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.